Insider buying last 90 days
No open-market insider purchases were filed for SRPT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SRPT insider filing, plotted on the chart in Gekko.Open SRPT in Gekko
NASDAQ: SRPT
Sarepta Therapeutics (SRPT) Stock Analysis & Forecast
Oct 12 close
$17.44−0.41 (−2.3%)
Gekko Brief
AI summaryOct 12 closeThis week brought several analyst actions alongside new clinical data on Sarepta Therapeutics' (SRPT) ELEVIDYS gene therapy. Bank of America Securities reaffirmed a Sell rating with an $18.00 price target, while RBC Capital cut its target to $17 from $19, keeping a Sector Perform, Speculative Risk rating. Separately, new two-year ELEVIDYS data in older Duchenne muscular dystrophy patients showed clinical benefits and a consistent safety profile, presented at the World Muscle Society congress and extending evidence to older patients while reinforcing protein expression in young children. Regenxbio and the University of Pennsylvania also settled a long-running gene-therapy patent dispute tied to Elevidys, dismissed with prejudice.
SRPT closed at $17.44, down 2.3%, sitting below both its 50-day average of $19.11 and 200-day average of $19.00. The stock has fallen 14.7% over one month and 20% over six months. The GekkoIndex reads 65.8, placing it in the Accumulation zone, down 0.7 over five days. Price sits 13.2% below Gekko Fair Value of $20.09.
Sarepta next reports earnings on 4 November 2026, after close, 23 days away and inside a typical 20-trading-day holding window; its last report showed EPS of $0.42 against an estimate of $0.34, with a 2.4% reaction, and it has beaten estimates in 4 of the last 8 quarters, with an average absolute reaction of 13%. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality from this point has averaged -10.8% over the next 20 trading days across 5 years, rising in 1 of them. Consensus among 16 firms includes 3 buy, 9 hold, and 4 sell ratings, with a consensus target of $21.64.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Sarepta Therapeutics price vs fair value
Close $17.44200-day averageGekko Fair Value $20.09
Sarepta Therapeutics quick facts
- Market cap
- $1.84B
- P/E ratio
- —
- Forward P/E
- 19.2
- EPS, TTM
- −$1.57
- Revenue, TTM
- $1.97B
- Profit margin
- -6.9%
- Dividend yield
- —
- Beta
- 0.38
- Volume
- 3.28M avg 2.74M
- 1-year return
- −24.6%
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±9.6%
- 50-day average
- $19.11
- 200-day average
- $19.00
- Next earnings
- Nov 4 after close
- Shares outstanding
- 105.6M
Sarepta Therapeutics swing-trade checklist
Sarepta Therapeutics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $17.44 sits between the 50-day ($19.11) and 200-day ($19.00) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.8, Accumulation
Reading 65.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
13.2% below
Price is 13.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−10.8% on average
From this point in the calendar, the next 20 trading days averaged −10.8% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Sarepta Therapeutics stock chart and price history
Sarepta Therapeutics closed at $17.44 on Oct 12, 2026, −24.6% over the past year, inside a 52-week range of $14.68 to $24.68.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −14.7%
- 3 months
- −2.9%
- 6 months
- −20.0%
- 1 year
- −24.6%
The full SRPT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SRPT in Gekko
Follow Sarepta Therapeutics through every session
Put SRPT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SRPT in GekkoFree for 7 days. No credit card required.
About Sarepta Therapeutics
Sarepta Therapeutics develops genetic medicines for rare diseases, working with RNA-targeted therapeutics and gene therapies. It is known for treating Duchenne muscular dystrophy, with two approved products already on the market: EXONDYS 51 for patients whose dystrophin gene mutations respond to exon 51 skipping, and VYONDYS 53 for those with exon 53 skipping mutations.
Beyond these approved therapies, the company is advancing a pipeline that includes AMONDYS 45, built on exon-skipping chemistry targeting exon 45, and SRP-5051, a peptide-conjugated compound aimed at exon 51 of dystrophin pre-mRNA. It is also pursuing gene therapy candidates SRP-9001 for Duchenne muscular dystrophy and SRP-9003 for limb-girdle muscular dystrophies. This work is carried out partly through partnerships with outside institutions, among them F. Hoffman-La Roche, Nationwide Children's Hospital, Lysogene, Duke University, Genethon and StrideBio.
Sarepta Therapeutics was founded in 1980 and is headquartered in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker SRPT.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- sarepta.com
Sarepta Therapeutics GekkoIndex: the smart money zone
Sarepta Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.8, in the Accumulation zone, down 0.7 points over five sessions.
65.8Accumulation
Down 0.7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 78 | +1.6% | +2.1% | ||
| Accumulation (current zone) | 288 | −0.9% | −2.7% | ||
| Neutral | 278 | −1.0% | −5.0% | ||
| Distribution | 35 | −2.7% | −7.5% | ||
| Selling | 3 | Too few readings yet | |||
Average SRPT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the SRPT price, zone by zone.Track SRPT in Gekko
Is Sarepta Therapeutics stock overvalued? Gekko Fair Value
Sarepta Therapeutics trades 13.2% below Gekko Fair Value of $20.09, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Sarepta Therapeutics shares are worth, recalculated every trading day.
$20.09
Gekko Fair Value, Oct 10, 2026
13.2% Undervalued
At the end of Aug 2026 the price was 1.6% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open SRPT in Gekko
Sarepta Therapeutics insider and Congress trading
No open-market insider purchases were filed for Sarepta Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SRPT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SRPT, plotted on the chart in Gekko.Open SRPT in Gekko
Buybacks
Sarepta Therapeutics has been buying back its own shares.
- Bought back, year ended Dec 31, 2025
- $25.01M
- As a share of market cap
- 1.36%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold SRPT.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Sarepta Therapeutics earnings: next date and track record
Sarepta Therapeutics reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- $0.11
- Revenue estimate
- $352.8M
4 of 8reports beat the EPS estimate
±13%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Sarepta delivered GAAP and non-GAAP operating profitability in Q2 2026, with cash and investments increasing approximately $197 million during the quarter. The PMO franchise remained stable while ELEVIDYS performed in line with expectations with improving enrollment forms. Management highlighted their siRNA pipeline with promising preclinical and early clinical data in FSHD and DM1. The company has 4 approved Duchenne therapies and upcoming regulatory decisions for VVYONDYS and AMONDYS.
- Guidance
- Sarepta narrowed 2026 total net product revenue guidance to $1.2 billion to $1.3 billion, with the midpoint as the primary reference. Key upcoming milestones include Cohort 8 data and new siRNA program data in H2 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.42 est $0.34 | $401.3M est $366.4M | +2.4% |
| May 6, 2026 | $3.16 est $1.05 | $730.8M est $474.2M | −4.5% |
| Feb 25, 2026 | −$3.58 est −$1.05 | $442.9M est $369.6M | −7.4% |
| Nov 3, 2025 | −$0.13 est $0.01 | $399.4M est $391.4M | −32.5% |
| Aug 6, 2025 | $2.02 est $1.11 | $611.1M est $342.9M | +7.2% |
| May 6, 2025 | −$3.42 est −$0.65 | $744.9M est $687.5M | −42.3% |
| Feb 26, 2025 | $1.90 est $2.06 | $658.4M est $631.0M | −3.6% |
| Nov 6, 2024 | $0.34 est −$0.13 | $467.2M est $407.2M | −3.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Sarepta Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Sarepta Therapeutics is $21.64, +24.1% from the last close, from 16 firms rating the stock in the last 90 days.
$21.64consensus 12-month target, +24.1% from the last close
Now $17.44Avg $21.64
Low $5High $38
Each firm’s latest rating in the last 90 days: 16 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 9 | Bank of America Securities | $18 | +3.2% |
| Oct 9 | RBC Capital | $17 | −2.5% |
| Oct 8 | RBC Capital | $17 | −2.5% |
| Oct 5 | H.C. Wainwright | $5 | −71.3% |
| Sep 30 | J.P. Morgan | $20 | +14.7% |
−2.7%average 20-day move after past Accumulation readings
−10.8%average move over the next 20 trading days in the last 5 years
±4.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Sarepta Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Sarepta Therapeutics averaged −10.8% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.1% | 3 of 5 |
| Next 10 trading days | −1.1% | 3 of 5 |
| Next 15 trading days | −7.1% | 3 of 5 |
| Next 20 trading days | −10.8% | 1 of 5 |
| Next 30 trading days | −14.0% | 1 of 5 |
For scale, SRPT’s typical 20-trading-day move in either direction is about 9.6%.
Sarepta Therapeutics market cap and key statistics
Sarepta Therapeutics’s market cap is $1.84B and revenue of $1.97B over the last twelve months.
Valuation
- Market cap
- $1.84B
- Forward P/E
- 19.2
- EPS, TTM
- −$1.57
- Gekko Fair Value
- $20.09
Trading
- Volume
- 3.28M
- Avg volume, 20 days
- 2.74M
- 52-week high
- $24.68
- 52-week low
- $14.68
- Shares outstanding
- 105.6M
Financials
- Revenue, TTM
- $1.97B
- Profit margin
- -6.9%
- Return on equity
- -9.5%
- Quarterly earnings growth, YoY
- +2,664.0%
Risk and income
- Beta
- 0.38
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±9.6%
Sarepta Therapeutics stock news this week
Coverage of Sarepta Therapeutics this week reads negative: 3 positive, 2 neutral and 7 negative headlines.
- Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)The Globe and Mail, Oct 10
- SAREPTA THERAPEUTICS, INC. : RBC CUTS TARGET PRICE TO $17 FROM $19Moomoo, Oct 9
- How Investors May Respond To Sarepta Therapeutics (SRPT) Wider ELEVIDYS Benefit DataSimply Wall Street, Oct 9
- (SRPT) Risk Channels and Responsive AllocationStock Traders Daily, Oct 9
- Regenxbio, Penn End Revived Sarepta Gene-Therapy Patent FightBloomberg Law News, Oct 8
- RBC Cuts Price Target on Sarepta Therapeutics to $17 From $19, Keeps Sector Perform, Speculative Riskwww.marketscreener.com, Oct 8
Sarepta Therapeutics peers
Sarepta Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Sarepta Therapeutics stock FAQ
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $1.84B at the Oct 12, 2026 close of $17.44, with 105.6M shares outstanding.
What is the Sarepta Therapeutics stock forecast?
The consensus analyst 12-month price target for Sarepta Therapeutics is $21.64, +24.1% from the last close. Of the 16 firms that rated the stock in the last 90 days, 3 rate it a buy, 9 a hold and 4 a sell. Gekko doesn’t publish price predictions of its own.
Is Sarepta Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Sarepta Therapeutics is undervalued: the Oct 12, 2026 close of $17.44 is 13.2% below Gekko Fair Value of $20.09. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Sarepta Therapeutics report earnings next?
Sarepta Therapeutics is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of $0.11 per share on revenue of $352.8M. Sarepta Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 13% on average across the report.
What is Sarepta Therapeutics’s 52-week high and low?
Sarepta Therapeutics’s 52-week high is $24.68 and its 52-week low is $14.68; it closed at $17.44 on Oct 12, 2026, −24.6% over the past year. Over the last five years the shares peaked at $173.25 on Jun 21, 2024.
Is Sarepta Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Sarepta Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.